Journal of Clinical & Experimental Pharmacology

Venkateswarlu Kanamarlapudi

Publications

• Review Article
  Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
  Author(s): Aiysha Thompson and Venkateswarlu KanamarlapudiAiysha Thompson and Venkateswarlu Kanamarlapudi
  
  t has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and type 2 diabetes is the most common form. Type 2 diabetes increases the risk of complications such as heart attacks, blindness, amputations and kidney failure. Glucagon like Peptide-1 (GLP-1) is an effective insulinotropic agent and therefore its effects on insulin secretion have been greatly examined for more than two decades. It is a polypeptide hormone secreted by the intestinal L-cells into the blood in response to food uptake. GLP-1 has a very short half-life in vivo due to the rapid proteolytic degradation by Dipeptidyl Peptidase IV (DPP-IV). Therefore DPP-IV resistant GLP-1 analogues, Exenatide and Liraglutide, have been developed and are currently being used in the treatment of type 2 diabetes. GLP-1 agonist functions by binding to its receptor, GLP1R, on the cell surf.. View More»
  DOI: 10.4172/2161-1459.1000138

  Abstract PDF